Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company specializing in cancer treatment drug development, has scheduled its full year 2024 financial results announcement and corporate update for March 13, 2025, at 8:30 a.m. Eastern Time. The company will make a replay of the conference call available through their Investor Relations website's Events section.
Cellectar Biosciences (NASDAQ: CLRB), un'azienda biopharmaceutica in fase avanzata specializzata nello sviluppo di farmaci per il trattamento del cancro, ha programmato l'annuncio dei risultati finanziari per l'intero anno 2024 e un aggiornamento aziendale per il 13 marzo 2025, alle 8:30 ora orientale. L'azienda renderà disponibile una registrazione della conferenza attraverso la sezione Eventi del suo sito web per le Relazioni con gli Investitori.
Cellectar Biosciences (NASDAQ: CLRB), una empresa biofarmacéutica en fase avanzada que se especializa en el desarrollo de medicamentos para el tratamiento del cáncer, ha programado el anuncio de sus resultados financieros del año completo 2024 y una actualización corporativa para el 13 de marzo de 2025, a las 8:30 a.m. hora del Este. La empresa hará disponible una repetición de la llamada de conferencia a través de la sección de Eventos en su sitio web de Relaciones con Inversores.
Cellectar Biosciences (NASDAQ: CLRB), 암 치료제 개발을 전문으로 하는 후기 단계의 임상 생명공학 회사는 2025년 3월 13일 오전 8시 30분 동부 표준시에 2024년 전체 연도 재무 결과 발표 및 기업 업데이트를 예정하고 있습니다. 회사는 투자자 관계 웹사이트의 이벤트 섹션을 통해 컨퍼런스 콜의 재생을 제공할 것입니다.
Cellectar Biosciences (NASDAQ: CLRB), une entreprise biopharmaceutique en phase avancée spécialisée dans le développement de médicaments pour le traitement du cancer, a programmé l'annonce de ses résultats financiers pour l'année complète 2024 et une mise à jour de l'entreprise pour le 13 mars 2025 à 8h30, heure de l'Est. L'entreprise mettra à disposition un enregistrement de la conférence via la section Événements de son site Web pour les relations avec les investisseurs.
Cellectar Biosciences (NASDAQ: CLRB), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf die Entwicklung von Krebsbehandlungsmedikamenten spezialisiert hat, hat die Bekanntgabe seiner finanziellen Ergebnisse für das Gesamtjahr 2024 und ein Unternehmensupdate für den 13. März 2025 um 8:30 Uhr Eastern Time angesetzt. Das Unternehmen wird eine Wiederholung der Telefonkonferenz über den Bereich Veranstaltungen auf seiner Investor-Relations-Website zur Verfügung stellen.
- None.
- None.
FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will report financial results for the full year ended December 31, 2024, and provide a corporate update on March 13, 2025, at 8:30 a.m. Eastern Time.
| Conference Call & Webcast Details: | |
| Date: | Thursday, March 13, 2025 |
| Time: | 8:30 am Eastern Time |
| Toll Free: | 1-800-717-1738 |
| Conference ID: Webcast: | 25759 Click HERE |
A replay of the call will be available on the Events section of the company’s Investor Relations website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes its lead assets: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope); CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer; and CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
In addition, iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, and the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications.
For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.
Investor Contact:
Anne Marie Fields
212-362-1200
Precision AQ (formerly Stern IR)
annemariefields@precisionaq.com
FAQ
When will Cellectar Biosciences (CLRB) release its 2024 annual financial results?
How can investors access CLRB's 2024 annual earnings call replay?
What is the main business focus of Cellectar Biosciences (CLRB)?
What time is CLRB's 2024 annual earnings conference call scheduled for?
